The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Prescription Weight Loss Pills Market Research Report 2025
Synopsis
Health care professionals use the Body Mass Index (BMI), a measure of people weight in relation to height, to define overweight and obesity. People who have a BMI between 25 and 30 are considered to be overweight. Obesity is defined as having a BMI of 30 or greater. Are overweight, obese, or severely obese, which may increase risk of developing health problems. Obesity is a chronic disease and prescription medications to treat overweight and obesity work in different ways. Prescription weight loss medicines can help obese people lose weight. They are usually prescribed by a doctor when diet and exercise alone are not working. Each of these medicines works differently. People who use these medicines may not feel as hungry. Or they may feel full after eating only a small amount of food. Another type of weight-loss medicine makes it harder for your body to absorb fat. Prescription weight loss drugs can be helpful when used in combination with a low-calorie diet and regular physical activity.
Global Prescription Weight Loss Pills market is projected to reach US$ 2625.3 million in 2029, increasing from US$ 1130 million in 2022, with the CAGR of 10.4% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Prescription Weight Loss Pills market research.
Rising conditions such as obesity, cardiovascular diseases, diabetes, and hypertension are increasing the revenue share of the global weight loss drugs market. Moreover, these drugs are used to maintain a healthy body weight amid growing adoption of a healthy lifestyle, thereby driving the expansion of the market revenue.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Prescription Weight Loss Pills market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Currax Pharmaceuticals (Contrave)
VIVUS (Qsymia)
Novo Nordisk A/S
Rhythm Pharmaceuticals (Imcivree)
Eli Lilly and Company (TRICARE)
CHEPLAPHARM (Xenical)
Pfizer
Teva Pharmaceutical (Actavis)
Haleon Group (alli)
Sanofi (Adlyxin)
AstraZeneca (BYDUREON BCise)
Segment by Type
Oral Tablets
Oral Capsules
Injections
Segment by Application
Hospital
Pharmacy
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Prescription Weight Loss Pills report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Health care professionals use the Body Mass Index (BMI), a measure of people weight in relation to height, to define overweight and obesity. People who have a BMI between 25 and 30 are considered to be overweight. Obesity is defined as having a BMI of 30 or greater. Are overweight, obese, or severely obese, which may increase risk of developing health problems. Obesity is a chronic disease and prescription medications to treat overweight and obesity work in different ways. Prescription weight loss medicines can help obese people lose weight. They are usually prescribed by a doctor when diet and exercise alone are not working. Each of these medicines works differently. People who use these medicines may not feel as hungry. Or they may feel full after eating only a small amount of food. Another type of weight-loss medicine makes it harder for your body to absorb fat. Prescription weight loss drugs can be helpful when used in combination with a low-calorie diet and regular physical activity.
Global Prescription Weight Loss Pills market is projected to reach US$ 2625.3 million in 2029, increasing from US$ 1130 million in 2022, with the CAGR of 10.4% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Prescription Weight Loss Pills market research.
Rising conditions such as obesity, cardiovascular diseases, diabetes, and hypertension are increasing the revenue share of the global weight loss drugs market. Moreover, these drugs are used to maintain a healthy body weight amid growing adoption of a healthy lifestyle, thereby driving the expansion of the market revenue.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Prescription Weight Loss Pills market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Currax Pharmaceuticals (Contrave)
VIVUS (Qsymia)
Novo Nordisk A/S
Rhythm Pharmaceuticals (Imcivree)
Eli Lilly and Company (TRICARE)
CHEPLAPHARM (Xenical)
Pfizer
Teva Pharmaceutical (Actavis)
Haleon Group (alli)
Sanofi (Adlyxin)
AstraZeneca (BYDUREON BCise)
Segment by Type
Oral Tablets
Oral Capsules
Injections
Segment by Application
Hospital
Pharmacy
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Prescription Weight Loss Pills report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index1 Prescription Weight Loss Pills Market Overview
1.1 Product Overview and Scope of Prescription Weight Loss Pills
1.2 Prescription Weight Loss Pills Segment by Type
1.2.1 Global Prescription Weight Loss Pills Market Value Comparison by Type (2023-2029)
1.2.2 Oral Tablets
1.2.3 Oral Capsules
1.2.4 Injections
1.3 Prescription Weight Loss Pills Segment by Application
1.3.1 Global Prescription Weight Loss Pills Market Value by Application: (2023-2029)
1.3.2 Hospital
1.3.3 Pharmacy
1.4 Global Prescription Weight Loss Pills Market Size Estimates and Forecasts
1.4.1 Global Prescription Weight Loss Pills Revenue 2018-2029
1.4.2 Global Prescription Weight Loss Pills Sales 2018-2029
1.4.3 Global Prescription Weight Loss Pills Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Prescription Weight Loss Pills Market Competition by Manufacturers
2.1 Global Prescription Weight Loss Pills Sales Market Share by Manufacturers (2018-2023)
2.2 Global Prescription Weight Loss Pills Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Prescription Weight Loss Pills Average Price by Manufacturers (2018-2023)
2.4 Global Prescription Weight Loss Pills Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Prescription Weight Loss Pills, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Prescription Weight Loss Pills, Product Type & Application
2.7 Prescription Weight Loss Pills Market Competitive Situation and Trends
2.7.1 Prescription Weight Loss Pills Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Prescription Weight Loss Pills Players Market Share by Revenue
2.7.3 Global Prescription Weight Loss Pills Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Prescription Weight Loss Pills Retrospective Market Scenario by Region
3.1 Global Prescription Weight Loss Pills Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Prescription Weight Loss Pills Global Prescription Weight Loss Pills Sales by Region: 2018-2029
3.2.1 Global Prescription Weight Loss Pills Sales by Region: 2018-2023
3.2.2 Global Prescription Weight Loss Pills Sales by Region: 2024-2029
3.3 Global Prescription Weight Loss Pills Global Prescription Weight Loss Pills Revenue by Region: 2018-2029
3.3.1 Global Prescription Weight Loss Pills Revenue by Region: 2018-2023
3.3.2 Global Prescription Weight Loss Pills Revenue by Region: 2024-2029
3.4 North America Prescription Weight Loss Pills Market Facts & Figures by Country
3.4.1 North America Prescription Weight Loss Pills Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Prescription Weight Loss Pills Sales by Country (2018-2029)
3.4.3 North America Prescription Weight Loss Pills Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Prescription Weight Loss Pills Market Facts & Figures by Country
3.5.1 Europe Prescription Weight Loss Pills Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Prescription Weight Loss Pills Sales by Country (2018-2029)
3.5.3 Europe Prescription Weight Loss Pills Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Prescription Weight Loss Pills Market Facts & Figures by Country
3.6.1 Asia Pacific Prescription Weight Loss Pills Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Prescription Weight Loss Pills Sales by Country (2018-2029)
3.6.3 Asia Pacific Prescription Weight Loss Pills Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Prescription Weight Loss Pills Market Facts & Figures by Country
3.7.1 Latin America Prescription Weight Loss Pills Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Prescription Weight Loss Pills Sales by Country (2018-2029)
3.7.3 Latin America Prescription Weight Loss Pills Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Prescription Weight Loss Pills Market Facts & Figures by Country
3.8.1 Middle East and Africa Prescription Weight Loss Pills Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Prescription Weight Loss Pills Sales by Country (2018-2029)
3.8.3 Middle East and Africa Prescription Weight Loss Pills Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Prescription Weight Loss Pills Sales by Type (2018-2029)
4.1.1 Global Prescription Weight Loss Pills Sales by Type (2018-2023)
4.1.2 Global Prescription Weight Loss Pills Sales by Type (2024-2029)
4.1.3 Global Prescription Weight Loss Pills Sales Market Share by Type (2018-2029)
4.2 Global Prescription Weight Loss Pills Revenue by Type (2018-2029)
4.2.1 Global Prescription Weight Loss Pills Revenue by Type (2018-2023)
4.2.2 Global Prescription Weight Loss Pills Revenue by Type (2024-2029)
4.2.3 Global Prescription Weight Loss Pills Revenue Market Share by Type (2018-2029)
4.3 Global Prescription Weight Loss Pills Price by Type (2018-2029)
5 Segment by Application
5.1 Global Prescription Weight Loss Pills Sales by Application (2018-2029)
5.1.1 Global Prescription Weight Loss Pills Sales by Application (2018-2023)
5.1.2 Global Prescription Weight Loss Pills Sales by Application (2024-2029)
5.1.3 Global Prescription Weight Loss Pills Sales Market Share by Application (2018-2029)
5.2 Global Prescription Weight Loss Pills Revenue by Application (2018-2029)
5.2.1 Global Prescription Weight Loss Pills Revenue by Application (2018-2023)
5.2.2 Global Prescription Weight Loss Pills Revenue by Application (2024-2029)
5.2.3 Global Prescription Weight Loss Pills Revenue Market Share by Application (2018-2029)
5.3 Global Prescription Weight Loss Pills Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Currax Pharmaceuticals (Contrave)
6.1.1 Currax Pharmaceuticals (Contrave) Corporation Information
6.1.2 Currax Pharmaceuticals (Contrave) Description and Business Overview
6.1.3 Currax Pharmaceuticals (Contrave) Prescription Weight Loss Pills Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Currax Pharmaceuticals (Contrave) Prescription Weight Loss Pills Product Portfolio
6.1.5 Currax Pharmaceuticals (Contrave) Recent Developments/Updates
6.2 VIVUS (Qsymia)
6.2.1 VIVUS (Qsymia) Corporation Information
6.2.2 VIVUS (Qsymia) Description and Business Overview
6.2.3 VIVUS (Qsymia) Prescription Weight Loss Pills Sales, Revenue and Gross Margin (2018-2023)
6.2.4 VIVUS (Qsymia) Prescription Weight Loss Pills Product Portfolio
6.2.5 VIVUS (Qsymia) Recent Developments/Updates
6.3 Novo Nordisk A/S
6.3.1 Novo Nordisk A/S Corporation Information
6.3.2 Novo Nordisk A/S Description and Business Overview
6.3.3 Novo Nordisk A/S Prescription Weight Loss Pills Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Novo Nordisk A/S Prescription Weight Loss Pills Product Portfolio
6.3.5 Novo Nordisk A/S Recent Developments/Updates
6.4 Rhythm Pharmaceuticals (Imcivree)
6.4.1 Rhythm Pharmaceuticals (Imcivree) Corporation Information
6.4.2 Rhythm Pharmaceuticals (Imcivree) Description and Business Overview
6.4.3 Rhythm Pharmaceuticals (Imcivree) Prescription Weight Loss Pills Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Rhythm Pharmaceuticals (Imcivree) Prescription Weight Loss Pills Product Portfolio
6.4.5 Rhythm Pharmaceuticals (Imcivree) Recent Developments/Updates
6.5 Eli Lilly and Company (TRICARE)
6.5.1 Eli Lilly and Company (TRICARE) Corporation Information
6.5.2 Eli Lilly and Company (TRICARE) Description and Business Overview
6.5.3 Eli Lilly and Company (TRICARE) Prescription Weight Loss Pills Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Eli Lilly and Company (TRICARE) Prescription Weight Loss Pills Product Portfolio
6.5.5 Eli Lilly and Company (TRICARE) Recent Developments/Updates
6.6 CHEPLAPHARM (Xenical)
6.6.1 CHEPLAPHARM (Xenical) Corporation Information
6.6.2 CHEPLAPHARM (Xenical) Description and Business Overview
6.6.3 CHEPLAPHARM (Xenical) Prescription Weight Loss Pills Sales, Revenue and Gross Margin (2018-2023)
6.6.4 CHEPLAPHARM (Xenical) Prescription Weight Loss Pills Product Portfolio
6.6.5 CHEPLAPHARM (Xenical) Recent Developments/Updates
6.7 Pfizer
6.6.1 Pfizer Corporation Information
6.6.2 Pfizer Description and Business Overview
6.6.3 Pfizer Prescription Weight Loss Pills Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Pfizer Prescription Weight Loss Pills Product Portfolio
6.7.5 Pfizer Recent Developments/Updates
6.8 Teva Pharmaceutical (Actavis)
6.8.1 Teva Pharmaceutical (Actavis) Corporation Information
6.8.2 Teva Pharmaceutical (Actavis) Description and Business Overview
6.8.3 Teva Pharmaceutical (Actavis) Prescription Weight Loss Pills Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Teva Pharmaceutical (Actavis) Prescription Weight Loss Pills Product Portfolio
6.8.5 Teva Pharmaceutical (Actavis) Recent Developments/Updates
6.9 Haleon Group (alli)
6.9.1 Haleon Group (alli) Corporation Information
6.9.2 Haleon Group (alli) Description and Business Overview
6.9.3 Haleon Group (alli) Prescription Weight Loss Pills Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Haleon Group (alli) Prescription Weight Loss Pills Product Portfolio
6.9.5 Haleon Group (alli) Recent Developments/Updates
6.10 Sanofi (Adlyxin)
6.10.1 Sanofi (Adlyxin) Corporation Information
6.10.2 Sanofi (Adlyxin) Description and Business Overview
6.10.3 Sanofi (Adlyxin) Prescription Weight Loss Pills Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Sanofi (Adlyxin) Prescription Weight Loss Pills Product Portfolio
6.10.5 Sanofi (Adlyxin) Recent Developments/Updates
6.11 AstraZeneca (BYDUREON BCise)
6.11.1 AstraZeneca (BYDUREON BCise) Corporation Information
6.11.2 AstraZeneca (BYDUREON BCise) Prescription Weight Loss Pills Description and Business Overview
6.11.3 AstraZeneca (BYDUREON BCise) Prescription Weight Loss Pills Sales, Revenue and Gross Margin (2018-2023)
6.11.4 AstraZeneca (BYDUREON BCise) Prescription Weight Loss Pills Product Portfolio
6.11.5 AstraZeneca (BYDUREON BCise) Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Prescription Weight Loss Pills Industry Chain Analysis
7.2 Prescription Weight Loss Pills Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Prescription Weight Loss Pills Production Mode & Process
7.4 Prescription Weight Loss Pills Sales and Marketing
7.4.1 Prescription Weight Loss Pills Sales Channels
7.4.2 Prescription Weight Loss Pills Distributors
7.5 Prescription Weight Loss Pills Customers
8 Prescription Weight Loss Pills Market Dynamics
8.1 Prescription Weight Loss Pills Industry Trends
8.2 Prescription Weight Loss Pills Market Drivers
8.3 Prescription Weight Loss Pills Market Challenges
8.4 Prescription Weight Loss Pills Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
